Everolimus with exemestane in elderly breast cancer patients – case report Case report
Article Sidebar
Published:
Mar 31, 2014
Keywords:
breast cancer, everolimus, exemestan, elderly
Main Article Content
Abstract
Treating elderly patients suffering from metastatic breast cancer still constitutes a significant therapeutic problem. The possibility of administering everolimus in combination with exemestane appears to be a promising therapeutic option in the case of hormone-dependent cancers, without HER2 receptor overexpression.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Jagiełło-Gruszfeld A. Everolimus with exemestane in elderly breast cancer patients – case report. OncoReview [Internet]. 2014Mar.31 [cited 2024Nov.23];4(1(13):33-6. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/357
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Didkowska J, Wojciechowska U, Zatoński W. Malignant tumours in Poland in 2011. National Cancer Registry.
2. Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol. 2013; 20: 48-61.
3. Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366: 520-9.
4. Paplomata E, Zelnak A, O’Regan R. Ewerolimus: side effect profile and management of toxicities in breast cancer. Future Oncol. 2012; 8(6): 651-657.
5. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012; 8(6): 651-7
6. Pritchard KI, Burris HA 3rd, Ito Y et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13(6): 421-432.e8.
2. Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol. 2013; 20: 48-61.
3. Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366: 520-9.
4. Paplomata E, Zelnak A, O’Regan R. Ewerolimus: side effect profile and management of toxicities in breast cancer. Future Oncol. 2012; 8(6): 651-657.
5. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012; 8(6): 651-7
6. Pritchard KI, Burris HA 3rd, Ito Y et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13(6): 421-432.e8.